Aptevo Therapeutics Current Ratio 2014-2022 | APVO

Aptevo Therapeutics current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Aptevo Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.03B $0.01B 3.16
2022-06-30 $0.03B $0.01B 4.48
2022-03-31 $0.04B $0.02B 1.75
2021-12-31 $0.05B $0.04B 1.51
2021-09-30 $0.06B $0.03B 1.82
2021-06-30 $0.07B $0.03B 2.13
2021-03-31 $0.06B $0.03B 2.14
2020-12-31 $0.05B $0.02B 3.25
2020-09-30 $0.03B $0.01B 4.13
2020-06-30 $0.01B $0.01B 1.50
2020-03-31 $0.02B $0.01B 2.12
2019-12-31 $0.03B $0.04B 0.78
2019-09-30 $0.04B $0.04B 0.99
2019-06-30 $0.04B $0.02B 2.63
2019-03-31 $0.06B $0.02B 3.15
2018-12-31 $0.05B $0.02B 2.77
2018-09-30 $0.06B $0.02B 3.91
2018-06-30 $0.07B $0.02B 3.66
2018-03-31 $0.08B $0.02B 4.47
2017-12-31 $0.10B $0.02B 5.14
2017-09-30 $0.12B $0.02B 7.76
2017-06-30 $0.07B $0.01B 5.66
2017-03-31 $0.08B $0.01B 5.35
2016-12-31 $0.07B $0.02B 3.65
2016-09-30 $0.08B $0.02B 5.21
2016-06-30 $0.04B $0.02B 2.34
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2014-12-31 $0.04B $0.02B 2.10
2013-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.012B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00